Galactosidase Market Size to Boost USD 2.90 Billion By 2032 | CAGR 6.3% - Published by Emergen Research

The global Galactosidase market size was USD 1.58 Billion in 2022 and is expected to register a rapid revenue CAGR of 6.3% during the forecast period. Rising demand for galactosidase from the Food & Beverage (F&B) industry and medical applications such as blood group conversion and rapid advancements in enzyme technology are key factors driving market revenue growth.

The galactosidase market encompasses enzymes used in various industrial applications, particularly in the food and beverage, pharmaceutical, and biotechnology sectors. Galactosidase enzymes, including α-galactosidase and β-galactosidase, play a crucial role in catalyzing the hydrolysis of galactosides into simpler sugars, such as glucose and galactose. This enzymatic activity finds widespread use in food processing, lactose intolerance management, and bioprocessing applications, driving the demand for galactosidase enzymes worldwide.

 The report is attuned with the latest market changes and economic landscape with regard to the currently unfolding COVID-19 pandemic. The crisis has affected the demand and supply pattern, as well as the trends of the industry. It has also brought an economic slowdown that has affected the business of the key manufacturers of the industry. The report estimates the impact of this crisis on the current scenario and future prospects and provides a post-COVID market scenario.

Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-sample/2854

Drivers of the Galactosidase Market :

Several factors drive the growth of the galactosidase market. In the food and beverage industry, the increasing demand for enzyme-modified products, including lactose-free dairy products and fruit juices, fuels the demand for galactosidase enzymes. Moreover, the rising prevalence of lactose intolerance among consumers has spurred the development of enzyme-based dietary supplements and digestive aids containing galactosidase to alleviate symptoms. Additionally, advancements in enzyme engineering and bioprocessing technologies have expanded the application scope of galactosidase enzymes in pharmaceuticals, biofuels, and other industrial sectors, driving market growth.

Growth Factors of the Galactosidase Market :

The galactosidase market is driven by various growth factors contributing to its expansion. One key factor is the growing consumer awareness and demand for clean-label and natural ingredients in food and beverage products, driving the adoption of enzyme-based solutions like galactosidase enzymes as alternatives to chemical additives. Furthermore, the increasing prevalence of lactose intolerance and dairy-related digestive disorders globally creates a significant market opportunity for galactosidase enzyme products designed to improve digestibility and enhance nutritional profiles. Additionally, ongoing research and development efforts aimed at enhancing the specificity, activity, and stability of galactosidase enzymes are expected to fuel market growth by expanding their application potential across diverse industries.

 Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @ https://www.emergenresearch.com/request-discount/2854

The report also discusses the key players involved in the market such as:

Biocompare, Megazyme Ltd., JINAN BESTZYME BIOENGINEERING CO., LTD., Prospec-Tany Technogene Ltd., Pharming Group N.V., ISU ABXIS, Protalix Biotherapeutics, Chiesi Limited, Aumgene Biosciences, Amano Enzyme, Inc., Novozymes, Bestochem, DuPont, Konochem Co., Ltd., Sangamo Therapeutics, Inc.

The report provides a thorough estimation of the overall impact of the pandemic on the Galactosidase Market and its vital segments. The report also discusses the impact of the pandemic across different regions of the market. It also offers a current and future assessment of the impact of the pandemic on the Galactosidase Market

Galactosidase Latest Industry Updates

On 5 May 2023, Chiesi announced the signing of Global Rare Strategies, a business unit of the Chiesi Group that provides innovative treatments and solutions for people with rare diseases. Protalix BioTherapeutics, Inc. ProCellEx enriches therapeutic proteins expressed through the proprietary plant cell-based expression system ProCellEx, which the European Commission (EC) has approved in the European Union (EU) for treatment of adult Fabry disease patients with PRX-102 (pegnigalsidase alfa) has been granted marketing approval.

On 22 February 2023, Sangamo Therapeutics, Inc., a genomic medicine company, announced updated preliminary data as of October 20, 2022, from the Phase 1/2 clinical study of STAAR evaluates isaralgagene civaparvovec, or ST-920, a wholly owned Gene therapy product candidate for the treatment of Fabry disease. These data, presenting new biomarker data and results from the first kidney biopsy in this study, show evidence of clinical benefit of isaralgagene civaparvovec in Fabry disease.

Direct Order Can Be Placed Through This Link [Exclusive Copy] @  https://www.emergenresearch.com/select-license/2854

Galactosidase Market Segment Analysis :

For the purpose of this report, Emergen Research has segmented the global galactosidase market on the basis of product, form, application, and region:

Product Outlook (Revenue, USD Billion; 2019-2032)
Alpha Galactosidase
Beta Galactosidase
Form Outlook (Revenue, USD Billion; 2019-2032)
Capsule
Tablet
Others
Application Outlook (Revenue, USD Billion; 2019-2032)
Food & Beverages (F&B)
Pharmaceuticals
Pulp and Paper
Feed
Others
Regional Outlook (Revenue, USD Billion; 2019-2032)
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Benelux
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Rest of APAC
Latin America
Brazil
Rest of LATAM
Middle East & Africa
Saudi Arabia
UAE
South Africa
Turkey
Rest of Middle East & Africa

 Browse Full Report Description + Research Methodology + Table of Content + Infographics @ https://www.emergenresearch.com/industry-report/galactosidase-market

Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Visit for More Insights: https://www.emergenresearch.com/insights

About Us:
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

This release was published on openPR.